Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

6

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Dopamine D1 receptor

6

Dopamine receptor

6

Anandamide amidohydrolase

1

Leukocyte elastase

1

Leukocyte proteinase 3

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

6

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1970

6

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Parkinson's disease

6

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

6

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

6

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Hoffman-La Roche

6

Steinkopf, W.|Buchheim, K.|Beythien, K.|Dudek, H.|Eisold, J.|Gall, J.|Jaeger, P.|Reumuth, H.t|Semenoff, A.s|Wemme, A.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

7

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

7

FDA UNII

7

PUBCHEM

7

EPA CompTox

5

SMS_ID

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTI-PARKINSON DRUGS

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

DOPAMINERGIC AGENTS

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Dopa and dopa derivatives

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

5

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 7 of 7 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

LEVODOPA

46627O600J

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

PHENYLMETHANESULFONYL FLUORIDE

57KD15003I

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Leukocyte elastase

Leukocyte proteinase 3

Anandamide amidohydrolase

Anandamide amidohydrolase

Conditions:

Phenylmethanesulfonyl fluoride is an irreversible inhibitor of serine proteases commonly used in the preparation of cell lysates. Phenylmethanesulfonyl fluoride has been used as a supplement in nuclear protein extraction and inhibitor of cholesterol ...

esterase (CE) and pseudocholinesterase (PCE). Administration of PMSF produces analgesia unrelated to its anticholinesterase effect and prolongs the analgesic effect of centrally administered β-endorphin. The physiological and toxicological properties of this compound have not been evaluated in humans.

BISMUTH SUBDOPATE

G69RN28K8B

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

FOSLEVODOPA

37NQZ0J76I

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

MELEVODOPA HYDROCHLORIDE

JFU1A8866V

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

MELEVODOPA

M30686U4X4

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

ETILEVODOPA

895X917GYE

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1